Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (7)

Search Parameters:
Authors = C. Alt

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
20 pages, 968 KiB  
Article
Ten-Year Results of a Single-Center Trial Investigating Heart Rate Control with Ivabradine or Metoprolol Succinate in Patients After Heart Transplantation
by Fabrice F. Darche, Alexandra C. Alt, Rasmus Rivinius, Matthias Helmschrott, Philipp Ehlermann, Norbert Frey and Ann-Kathrin Rahm
J. Cardiovasc. Dev. Dis. 2025, 12(8), 297; https://doi.org/10.3390/jcdd12080297 (registering DOI) - 1 Aug 2025
Abstract
Aims: Sinus tachycardia after heart transplantation (HTX) due to cardiac graft denervation is associated with reduced post-transplant survival and requires adequate treatment. We analyzed the long-term effects of heart rate control with ivabradine or metoprolol succinate in HTX recipients. Methods: This observational retrospective [...] Read more.
Aims: Sinus tachycardia after heart transplantation (HTX) due to cardiac graft denervation is associated with reduced post-transplant survival and requires adequate treatment. We analyzed the long-term effects of heart rate control with ivabradine or metoprolol succinate in HTX recipients. Methods: This observational retrospective single-center study analyzed the ten-year results of 110 patients receiving ivabradine (n = 54) or metoprolol succinate (n = 56) after HTX. Analysis included comparison of demographics, medications, heart rates, blood pressure values, echocardiographic features, cardiac catheterization data, cardiac biomarkers, and post-transplant survival including causes of death. Results: Both groups showed no significant differences concerning demographics or medications (except for ivabradine and metoprolol succinate). At 10-year follow-up, HTX recipients with ivabradine showed a significantly lower heart rate (72.7 ± 8.5 bpm) compared to baseline (88.8 ± 7.6 bpm; p < 0.001) and to metoprolol succinate (80.1 ± 8.1 bpm; p < 0.001), a significantly lower NT-proBNP level (588.4 ± 461.4 pg/mL) compared to baseline (3849.7 ± 1960.0 pg/mL; p < 0.001) and to metoprolol succinate (1229.0 ± 1098.6 pg/mL; p = 0.005), a significantly lower overall mortality (20.4% versus 46.4%; p = 0.004), and mortality due to graft failure (1.9% versus 21.4%; p = 0.001). Multivariate analysis showed a significantly decreased risk of death within 10 years after HTX in patients with post-transplant use of ivabradine (HR 0.374, CI 0.182–0.770; p = 0.008). Conclusions: In this single-center trial, patients with ivabradine revealed a significantly more pronounced heart rate reduction, a lower NT-proBNP level, and a superior 10-year survival after HTX. Full article
(This article belongs to the Collection Current Challenges in Heart Failure and Cardiac Transplantation)
Show Figures

Figure 1

37 pages, 18532 KiB  
Article
Regeneration of Biomechanically Functional Tendon Tissue Following Injection of Uncultured, Autologous, Adipose-Derived Regenerative Cells into Partial Achilles Tendon Defects in Rabbits
by Christoph Schmitz, Christopher Alt, Tobias Wuerfel, Stefan Milz, Jacqueline Dinzey, Ashley Hill, Katie J. Sikes, Lindsey H. Burton, Jeremiah Easley, Holly L. Stewart, Christian M. Puttlitz, Benjamin C. Gadomski, Kevin M. Labus, David A. Pearce, Nicola Maffulli and Eckhard U. Alt
Int. J. Mol. Sci. 2025, 26(14), 6800; https://doi.org/10.3390/ijms26146800 - 16 Jul 2025
Viewed by 506
Abstract
Current treatment strategies for partial tendon tears often lack the capacity to promote true tissue regeneration and improve long-term clinical outcomes. This study tested the hypothesis that treatment of a partial defect in the rabbit common calcaneus tendon (CCT) with uncultured, unmodified, autologous, [...] Read more.
Current treatment strategies for partial tendon tears often lack the capacity to promote true tissue regeneration and improve long-term clinical outcomes. This study tested the hypothesis that treatment of a partial defect in the rabbit common calcaneus tendon (CCT) with uncultured, unmodified, autologous, adipose-derived regenerative cells (UA-ADRCs) enables regenerative healing without scar formation. A full-thickness, 3 mm defect was produced in the midsubstance of the right gastrocnemius tendon, a component of the CCT, in adult female New Zealand white rabbits. Animals received either an injection of 28.3 × 106 UA-ADRCs in 0.5 mL Ringer’s lactated solution (RLS) or saline, or RLS or saline alone as sham treatment. Tendons were analyzed 4 or 12 weeks post-treatment using histology, immunohistochemistry and non-destructive biomechanical testing. UA-ADRC-treated tendons showed newly formed connective tissue consistent with tendon regeneration, whereas sham-treated tendons developed scar tissue. Biomechanical testing showed significantly higher percent relaxation in UA-ADRC-treated tendons compared to sham controls (p < 0.05), indicating greater viscoelasticity characteristic of healthy or well-integrated tissue. Together, these findings suggest that UA-ADRC therapy may provide a regenerative, structure-modifying treatment for partial tendon tears. Full article
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
Show Figures

Figure 1

11 pages, 1417 KiB  
Article
Proximal Humerus Fractures in the Elderly U.S. Population: A Cross-Sectional Study of Treatment Trends and Comparison of Complication Rates after Joint Replacement, Open Reduction and Internal Fixation, and Non-Surgical Management
by Nike Walter, Dominik Szymski, Moritz Riedl, Steven M. Kurtz, Volker Alt, David W. Lowenberg, Edmund C. Lau and Markus Rupp
J. Clin. Med. 2023, 12(10), 3506; https://doi.org/10.3390/jcm12103506 - 17 May 2023
Cited by 10 | Viewed by 2149
Abstract
Proximal humerus fracture (PHF) treatment remains challenging. Multiple therapy options exist, and the optimal choice of management has been increasingly discussed in the literature. The aim of this study was to (1) analyze trends in the propensity of proximal humerus fracture treatments and [...] Read more.
Proximal humerus fracture (PHF) treatment remains challenging. Multiple therapy options exist, and the optimal choice of management has been increasingly discussed in the literature. The aim of this study was to (1) analyze trends in the propensity of proximal humerus fracture treatments and (2) compare complication rates after joint replacement, surgical repair, and non-surgical treatment in terms of mechanical complications, union failure, and infection rates. In this cross-sectional study, patients aged 65 years or older with proximal humerus fractures occurring between 1 January 2009 and 31 December 2019 were identified from Medicare physician service claims records. The Kaplan–Meier method with the Fine and Gray adjustment was used to calculate the cumulative incidence rates for malunion/nonunion, infection, and mechanical complications for the following treatment categories: shoulder arthroplasty, open reduction and internal fixation (ORIF), and non-surgical treatment, respectively. Semiparametric Cox regression was performed incorporating 23 demographic, clinical, and socioeconomic covariates to determine risk factors. Between 2009 through 2019, conservative procedures decreased by 0.9%. ORIF procedures decreased from 9.51% (95% CI: 8.7–10.4) to 6.95% (95% CI: 6.2–7.7), whereas shoulder arthroplasties rose from 1.99% (95% CI: 1.6–2.4), to 5.45% (95% CI: 4.8–6.2). PHFs managed through ORIF were associated with higher union failure rates compared to conservatively treated fractures (HR = 1.31, 95% CI: 1.15–1.5, p < 0.001). The risk of developing an infection was increased after joint replacement compared to ORIF (2.66% vs. 1.09%, HR = 2.09, 95% CI: 1.46–2.98, p < 0.001). Mechanical complications were more common after joint replacement (6.37% vs. 4.85%, HR = 1.66, 95% CI: 1.32–2.09, p < 0.001). Complication rates differed significantly across treatment modalities. This should be considered when choosing a management procedure. Vulnerable elderly patient cohorts could be identified, and the optimization of modifiable risk factors might lead to a decrease of complication rates in both surgically and non-surgically treated patients. Full article
(This article belongs to the Section Orthopedics)
Show Figures

Figure 1

9 pages, 1129 KiB  
Article
Revision Rates and Associated Risk Factors after Shoulder Arthroplasty
by Nike Walter, David W. Lowenberg, Steven M. Kurtz, Volker Alt, Edmund C. Lau and Markus Rupp
J. Clin. Med. 2022, 11(24), 7256; https://doi.org/10.3390/jcm11247256 - 7 Dec 2022
Cited by 15 | Viewed by 2393
Abstract
This study aims at answering the following questions (1) How high is the revision rate after osteoarthritis-, and rotator cuff-related compared to proximal humerus fracture (PHF)-related shoulder arthroplasty? (2) What are the associated risk factors for a revision after shoulder arthroplasty? Shoulder arthroplasty [...] Read more.
This study aims at answering the following questions (1) How high is the revision rate after osteoarthritis-, and rotator cuff-related compared to proximal humerus fracture (PHF)-related shoulder arthroplasty? (2) What are the associated risk factors for a revision after shoulder arthroplasty? Shoulder arthroplasty procedures occurring between 1 January 2009 and 31 December 2019 were identified from the Medicare database. First, revision rates for PHF patients and age- and sex-matched non-fracture patients, grouped into osteoarthritis-related and rotator cuff-related arthroplasty, were compared. Second, revision rates between total shoulder arthroplasty and hemiarthroplasty after PHF were compared. Semiparametric Cox regression was applied, incorporating 23 demographic, clinical, and socioeconomic covariates, to investigate risk factors for revision surgery. Between the considered time period from 2009 through 2019, a total number of 47,979 PHFs was identified. A shoulder arthroplasty procedure was performed in n = 2639 (5.5%, 95%CI: 4.8–6.1) of the cases. The five-year survivorship of the implant was 96.3 (95%CI: 93.8–97.9) after hemiarthroplasty and 96.1% (05%CI: 94.2–97.3) after total shoulder arthroplasty. To compare the revision rates, n = 14,775 patients with osteoarthritis and n = 4268 patients with rotator cuff arthropathy, who received a shoulder arthroplasty, served as a non-fracture control group. Patients receiving a rotator cuff-related arthroplasty were more likely to require a revision compared to patients treated for osteoarthritis (HR: 1.27, 95%CI: 1.04–1.44, p = 0.018). Identified significant risk factors for revision surgery after shoulder arthroplasty included age ≤ 75 years, male sex, and osteoporosis. High implant survival was found for hemiarthroplasty and total shoulder arthroplasty for the treatment of PHF in elderly patients. The risk of revision surgery was elevated in patients receiving a rotator cuff-related arthroplasty as well as in patients with osteoporosis, male patients and patients older than 75 years. Full article
(This article belongs to the Section Orthopedics)
Show Figures

Figure 1

250 pages, 84542 KiB  
Article
Deep Underground Neutrino Experiment (DUNE) Near Detector Conceptual Design Report
by A. Abed Abud, B. Abi, R. Acciarri, M. A. Acero, G. Adamov, D. Adams, M. Adinolfi, A. Aduszkiewicz, Z. Ahmad, J. Ahmed, T. Alion, S. Alonso Monsalve, M. Alrashed, C. Alt, A. Alton, P. Amedo, J. Anderson, C. Andreopoulos, M. P. Andrews, F. Andrianala, S. Andringa, N. Anfimov, A. Ankowski, M. Antonova, S. Antusch, A. Aranda-Fernandez, A. Ariga, L. O. Arnold, M. A. Arroyave, J. Asaadi, A. Aurisano, V. Aushev, D. Autiero, M. Ayala-Torres, F. Azfar, A. Back, H. Back, J. J. Back, C. Backhouse, P. Baesso, I. Bagaturia, L. Bagby, S. Balasubramanian, P. Baldi, B. Baller, B. Bambah, F. Barao, G. Barenboim, G. J. Barker, W. Barkhouse, C. Barnes, G. Barr, J. Barranco Monarca, N. Barros, J. L. Barrow, A. Basharina-Freshville, A. Bashyal, V. Basque, E. Belchior, J. B. R. Battat, F. Battisti, F. Bay, J. L. Bazo Alba, J. F. Beacom, E. Bechetoille, B. Behera, L. Bellantoni, G. Bellettini, V. Bellini, O. Beltramello, D. Belver, N. Benekos, F. Bento Neves, S. Berkman, P. Bernardini, R. M. Berner, H. Berns, S. Bertolucci, M. Betancourt, A. Betancur Rodríguez, M. Bhattacharjee, S. Bhuller, B. Bhuyan, S. Biagi, J. Bian, M. Biassoni, K. Biery, B. Bilki, M. Bishai, A. Bitadze, A. Blake, F. D. M. Blaszczyk, G. C. Blazey, E. Blucher, J. Boissevain, S. Bolognesi, T. Bolton, L. Bomben, M. Bonesini, M. Bongrand, F. Bonini, A. Booth, C. Booth, S. Bordoni, A. Borkum, T. Boschi, N. Bostan, P. Bour, C. Bourgeois, S. B. Boyd, D. Boyden, J. Bracinik, D. Braga, D. Brailsford, A. Brandt, J. Bremer, C. Brew, E. Brianne, S. J. Brice, C. Brizzolari, C. Bromberg, G. Brooijmans, J. Brooke, A. Bross, G. Brunetti, M. Brunetti, N. Buchanan, H. Budd, I. Cagnoli, D. Caiulo, P. Calafiura, J. Calcutt, M. Calin, S. Calvez, E. Calvo, A. Caminata, M. Campanelli, K. Cankocak, D. Caratelli, G. Carini, B. Carlus, P. Carniti, I. Caro Terrazas, H. Carranza, T. Carroll, J. F. Castaño Forero, A. Castillo, C. Castromonte, E. Catano-Mur, C. Cattadori, F. Cavalier, F. Cavanna, S. Centro, G. Cerati, A. Cervelli, A. Cervera Villanueva, M. Chalifour, A. Chappell, E. Chardonnet, N. Charitonidis, A. Chatterjee, S. Chattopadhyay, H. Chen, M. Chen, Y. Chen, Z. Chen, D. Cherdack, C. Chi, S. Childress, A. Chiriacescu, G. Chisnall, K. Cho, S. Choate, D. Chokheli, S. Choubey, A. Christensen, D. Christian, G. Christodoulou, A. Chukanov, E. Church, V. Cicero, P. Clarke, T. E. Coan, A. G. Cocco, J. A. B. Coelho, E. Conley, R. Conley, J. M. Conrad, M. Convery, S. Copello, L. Corwin, L. Cremaldi, L. Cremonesi, J. I. Crespo-Anadón, E. Cristaldo, R. Cross, A. Cudd, C. Cuesta, Y. Cui, D. Cussans, M. Dabrowski, O. Dalager, H. da Motta, L. Da Silva Peres, C. David, Q. David, G. S. Davies, S. Davini, J. Dawson, K. De, R. M. De Almeida, P. Debbins, I. De Bonis, M. P. Decowski, A. de Gouvêa, P. C. De Holanda, I. L. De Icaza Astiz, A. Deisting, P. De Jong, A. Delbart, D. Delepine, M. Delgado, A. Dell’Acqua, P. De Lurgio, J. R. T. de Mello Neto, D. M. DeMuth, S. Dennis, C. Densham, G. W. Deptuch, A. De Roeck, V. De Romeri, G. De Souza, R. Dharmapalan, F. Diaz, J. S. Díaz, S. Di Domizio, L. Di Giulio, P. Ding, L. Di Noto, C. Distefano, R. Diurba, M. Diwan, Z. Djurcic, N. Dokania, S. Dolan, M. J. Dolinski, L. Domine, D. Douglas, D. Douillet, G. Drake, F. Drielsma, D. Duchesneau, K. Duffy, P. Dunne, T. Durkin, H. Duyang, O. Dvornikov, D. A. Dwyer, A. S. Dyshkant, M. Eads, A. Earle, D. Edmunds, J. Eisch, L. Emberger, S. Emery, A. Ereditato, C. O. Escobar, G. Eurin, J. J. Evans, E. Ewart, A. C. Ezeribe, K. Fahey, A. Falcone, C. Farnese, Y. Farzan, J. Felix, M. Fernandes Carneiro da Silva, E. Fernandez-Martinez, P. Fernandez Menendez, F. Ferraro, L. Fields, F. Filthaut, A. Fiorentini, R. S. Fitzpatrick, W. Flanagan, B. Fleming, R. Flight, D. V. Forero, J. Fowler, W. Fox, J. Franc, K. Francis, D. Franco, J. Freeman, J. Freestone, J. Fried, A. Friedland, S. Fuess, I. Furic, A. P. Furmanski, A. Gabrielli, A. Gago, H. Gallagher, A. Gallas, A. Gallego-Ros, N. Gallice, V. Galymov, E. Gamberini, T. Gamble, R. Gandhi, R. Gandrajula, F. Gao, S. Gao, D. Garcia-Gamez, M. Á. García-Peris, S. Gardiner, D. Gastler, G. Ge, B. Gelli, A. Gendotti, S. Gent, Z. Ghorbani-Moghaddam, D. Gibin, I. Gil-Botella, S. Gilligan, C. Girerd, A. K. Giri, D. Gnani, O. Gogota, M. Gold, S. Gollapinni, K. Gollwitzer, R. A. Gomes, L. V. Gomez Bermeo, L. S. Gomez Fajardo, F. Gonnella, J. A. Gonzalez-Cuevas, D. Gonzalez-Diaz, M. Gonzalez-Lopez, M. C. Goodman, O. Goodwin, S. Goswami, C. Gotti, E. Goudzovski, C. Grace, M. Graham, R. Gran, E. Granados, P. Granger, A. Grant, C. Grant, D. Gratieri, P. Green, L. Greenler, J. Greer, W. C. Griffith, M. Groh, J. Grudzinski, K. Grzelak, W. Gu, V. Guarino, R. Guenette, E. Guerard, M. Guerzoni, A. Guglielmi, B. Guo, K. K. Guthikonda, R. Gutierrez, P. Guzowski, M. M. Guzzo, S. Gwon, A. Habig, H. Hadavand, R. Haenni, A. Hahn, J. Haiston, P. Hamacher-Baumann, T. Hamernik, P. Hamilton, J. Han, D. A. Harris, J. Hartnell, J. Harton, T. Hasegawa, C. Hasnip, R. Hatcher, K. W. Hatfield, A. Hatzikoutelis, C. Hayes, E. Hazen, A. Heavey, K. M. Heeger, J. Heise, K. Hennessy, S. Henry, M. A. Hernandez Morquecho, K. Herner, L. Hertel, J. Hewes, A. Higuera, T. Hill, S. J. Hillier, A. Himmel, J. Hoff, C. Hohl, A. Holin, E. Hoppe, G. A. Horton-Smith, M. Hostert, A. Hourlier, B. Howard, R. Howell, J. Huang, J. Huang, J. Hugon, G. Iles, N. Ilic, A. M. Iliescu, R. Illingworth, G. Ingratta, A. Ioannisian, L. Isenhower, R. Itay, A. Izmaylov, S. Jackson, V. Jain, E. James, B. Jargowsky, F. Jediny, D. Jena, Y. S. Jeong, C. Jesús-Valls, X. Ji, L. Jiang, S. Jiménez, A. Jipa, R. Johnson, N. Johnston, B. Jones, S. B. Jones, M. Judah, C. K. Jung, T. Junk, Y. Jwa, M. Kabirnezhad, A. Kaboth, I. Kadenko, I. Kakorin, F. Kamiya, N. Kaneshige, G. Karagiorgi, G. Karaman, A. Karcher, M. Karolak, Y. Karyotakis, S. Kasai, S. P. Kasetti, L. Kashur, N. Kazaryan, E. Kearns, P. Keener, K. J. Kelly, E. Kemp, O. Kemularia, W. Ketchum, S. H. Kettell, M. Khabibullin, A. Khotjantsev, A. Khvedelidze, D. Kim, B. King, B. Kirby, M. Kirby, J. Klein, K. Koehler, L. W. Koerner, S. Kohn, P. P. Koller, L. Kolupaeva, M. Kordosky, T. Kosc, U. Kose, V. A. Kostelecký, K. Kothekar, F. Krennrich, I. Kreslo, Y. Kudenko, V. A. Kudryavtsev, S. Kulagin, J. Kumar, P. Kumar, R. Kumar, P. Kunze, N. Kurita, C. Kuruppu, V. Kus, T. Kutter, A. Lambert, B. Land, K. Lande, C. E. Lane, K. Lang, T. Langford, J. Larkin, P. Lasorak, D. Last, C. Lastoria, A. Laundrie, G. Laurenti, A. Lawrence, I. Lazanu, R. LaZur, T. Le, S. Leardini, J. Learned, P. LeBrun, T. LeCompte, G. Lehmann Miotto, R. Lehnert, M. A. Leigui de Oliveira, M. Leitner, L. Li, S. W. Li, T. Li, Y. Li, H. Liao, C. S. Lin, Q. Lin, S. Lin, A. Lister, B. R. Littlejohn, J. Liu, S. Lockwitz, T. Loew, M. Lokajicek, I. Lomidze, K. Long, K. Loo, D. Lorca, T. Lord, J. M. LoSecco, W. C. Louis, X. G. Lu, K. B. Luk, X. Luo, N. Lurkin, T. Lux, V. P. Luzio, D. MacFarlane, A. A. Machado, P. Machado, C. T. Macias, J. R. Macier, A. Maddalena, A. Madera, P. Madigan, S. Magill, K. Mahn, A. Maio, A. Major, J. A. Maloney, G. Mandrioli, R. C. Mandujano, J. Maneira, L. Manenti, S. Manly, A. Mann, K. Manolopoulos, M. Manrique Plata, V. N. Manyam, L. Manzanillas, M. Marchan, A. Marchionni, W. Marciano, D. Marfatia, C. Mariani, J. Maricic, R. Marie, F. Marinho, A. D. Marino, D. Marsden, M. Marshak, C. M. Marshall, J. Marshall, J. Marteau, J. Martin-Albo, N. Martinez, D. A. Martinez Caicedo, S. Martynenko, K. Mason, A. Mastbaum, M. Masud, S. Matsuno, J. Matthews, C. Mauger, N. Mauri, K. Mavrokoridis, I. Mawby, R. Mazza, A. Mazzacane, E. Mazzucato, T. McAskill, E. McCluskey, N. McConkey, K. S. McFarland, C. McGrew, A. McNab, A. Mefodiev, P. Mehta, P. Melas, O. Mena, S. Menary, H. Mendez, D. P. Méndez, A. Menegolli, G. Meng, M. D. Messier, W. Metcalf, T. Mettler, M. Mewes, H. Meyer, T. Miao, G. Michna, T. Miedema, J. Migenda, V. Mikola, R. Milincic, W. Miller, J. Mills, C. Milne, O. Mineev, O. G. Miranda, S. Miryala, C. S. Mishra, S. R. Mishra, A. Mislivec, D. Mladenov, I. Mocioiu, K. Moffat, N. Moggi, R. Mohanta, T. A. Mohayai, N. Mokhov, J. Molina, L. Molina Bueno, A. Montanari, C. Montanari, D. Montanari, E. Montagna, L. M. Montano Zetina, J. Moon, M. Mooney, A. F. Moor, D. Moreno, C. Morris, C. Mossey, E. Motuk, C. A. Moura, J. Mousseau, W. Mu, L. Mualem, J. Mueller, M. Muether, S. Mufson, F. Muheim, A. Muir, M. Mulhearn, D. Munford, H. Muramatsu, S. Murphy, J. Musser, J. Nachtman, S. Nagu, M. Nalbandyan, R. Nandakumar, D. Naples, S. Narita, D. Navas-Nicolás, A. Navrer-Agasson, N. Nayak, M. Nebot-Guinot, K. Negishi, J. K. Nelson, J. Nesbit, M. Nessi, D. Newbold, M. Newcomer, D. Newhart, H. Newton, M. Niccolo, R. Nichol, F. Nicolas-Arnaldos, M. Nicoletta, E. Niner, K. Nishimura, A. Norman, A. Norrick, R. Northrop, P. Novella, J. A. Nowak, M. Oberling, J. P. Ochoa-Ricoux, A. Olivares Del Campo, A. Olivier, A. Olshevskiy, Y. Onel, Y. Onishchuk, J. Ott, L. Pagani, S. Pakvasa, G. Palacio, O. Palamara, S. Palestini, J. M. Paley, M. Pallavicini, C. Palomares, J. L. Palomino-Gallo, E. Pantic, V. Paolone, V. Papadimitriou, R. Papaleo, A. Papanestis, S. Paramesvaran, S. Parke, Z. Parsa, M. Parvu, S. Pascoli, L. Pasqualini, J. Pasternak, J. Pater, C. Patrick, L. Patrizii, R. B. Patterson, S. J. Patton, T. Patzak, A. Paudel, B. Paulos, L. Paulucci, Z. Pavlovic, G. Pawloski, D. Payne, V. Pec, S. J. M. Peeters, E. Pennacchio, A. Penzo, O. L. G. Peres, J. Perry, D. Pershey, G. Pessina, G. Petrillo, C. Petta, R. Petti, F. Piastra, L. Pickering, F. Pietropaolo, R. Plunkett, R. Poling, X. Pons, N. Poonthottathil, F. Poppi, S. Pordes, J. Porter, M. Potekhin, R. Potenza, B. V. K. S. Potukuchi, J. Pozimski, M. Pozzato, S. Prakash, T. Prakash, S. Prince, D. Pugnere, X. Qian, M. C. Queiroga Bazetto, J. L. Raaf, V. Radeka, J. Rademacker, B. Radics, A. Rafique, E. Raguzin, M. Rai, M. Rajaoalisoa, I. Rakhno, A. Rakotonandrasana, L. Rakotondravohitra, Y. A. Ramachers, R. Rameika, M. A. Ramirez Delgado, B. Ramson, A. Rappoldi, G. Raselli, P. Ratoff, S. Raut, R. F. Razakamiandra, J. S. Real, B. Rebel, M. Reggiani-Guzzo, T. Rehak, J. Reichenbacher, S. D. Reitzner, H. Rejeb Sfar, A. Renshaw, S. Rescia, F. Resnati, A. Reynolds, C. Riccio, G. Riccobene, L. C. J. Rice, J. Ricol, A. Rigamonti, Y. Rigaut, D. Rivera, L. Rochester, M. Roda, P. Rodrigues, M. J. Rodriguez Alonso, E. Rodriguez Bonilla, J. Rodriguez Rondon, S. Rosauro-Alcaraz, M. Rosenberg, P. Rosier, B. Roskovec, M. Rossella, J. Rout, P. Roy, S. Roy, A. Rubbia, C. Rubbia, F. C. Rubio, B. Russell, D. Ruterbories, R. Saakyan, S. Sacerdoti, T. Safford, R. Sahay, N. Sahu, P. Sala, N. Samios, O. Samoylov, M. C. Sanchez, D. A. Sanders, D. Sankey, S. Santana, M. Santos-Maldonado, N. Saoulidou, P. Sapienza, C. Sarasty, I. Sarcevic, G. Savage, V. Savinov, A. Scaramelli, A. Scarff, A. Scarpelli, T. Schaffer, H. Schellman, P. Schlabach, D. Schmitz, K. Scholberg, A. Schukraft, E. Segreto, J. Sensenig, I. Seong, A. Sergi, D. Sgalaberna, M. H. Shaevitz, S. Shafaq, M. Shamma, R. Sharankova, H. R. Sharma, R. Sharma, T. Shaw, C. Shepherd-Themistocleous, S. Shin, D. Shooltz, R. Shrock, L. Simard, F. Simon, N. Simos, J. Sinclair, G. Sinev, J. Singh, J. Singh, V. Singh, R. Sipos, F. W. Sippach, G. Sirri, A. Sitraka, K. Siyeon, K. Skarpaas VIII, A. Smith, E. Smith, P. Smith, J. Smolik, M. Smy, E. L. Snider, P. Snopok, M. Soares Nunes, H. Sobel, M. Soderberg, C. J. Solano Salinas, S. Söldner-Rembold, S. Soleti, N. Solomey, V. Solovov, W. E. Sondheim, M. Sorel, J. Soto-Oton, A. Sousa, K. Soustruznik, F. Spagliardi, M. Spanu, J. Spitz, N. J. C. Spooner, K. Spurgeon, R. Staley, M. Stancari, L. Stanco, R. Stanley, R. Stein, H. M. Steiner, J. Stewart, B. Stillwell, J. Stock, F. Stocker, T. Stokes, M. Strait, T. Strauss, S. Striganov, A. Stuart, J. G. Suarez, H. Sullivan, D. Summers, A. Surdo, V. Susic, L. Suter, C. M. Sutera, R. Svoboda, B. Szczerbinska, A. M. Szelc, R. Talaga, H. A. Tanaka, B. Tapia Oregui, A. Tapper, S. Tariq, E. Tatar, R. Tayloe, A. M. Teklu, M. Tenti, K. Terao, C. A. Ternes, F. Terranova, G. Testera, A. Thea, J. L. Thompson, C. Thorn, S. C. Timm, J. Todd, A. Tonazzo, D. Torbunov, M. Torti, M. Tortola, F. Tortorici, D. Totani, M. Toups, C. Touramanis, N. Tosi, R. Travaglini, J. Trevor, S. Trilov, W. H. Trzaska, Y. T. Tsai, Z. Tsamalaidze, K. V. Tsang, N. Tsverava, S. Tufanli, C. Tull, E. Tyley, M. Tzanov, M. A. Uchida, J. Urheim, T. Usher, S. Uzunyan, M. R. Vagins, P. Vahle, G. A. Valdiviesso, E. Valencia, P. Valerio, Z. Vallari, J. W. F. Valle, S. Vallecorsa, R. Van Berg, R. G. Van de Water, F. Varanini, D. Vargas, G. Varner, J. Vasel, S. Vasina, G. Vasseur, N. Vaughan, K. Vaziri, S. Ventura, A. Verdugo, S. Vergani, M. A. Vermeulen, M. Verzocchi, M. Vicenzi, H. Vieira de Souza, C. Vignoli, C. Vilela, B. Viren, T. Vrba, T. Wachala, A. V. Waldron, M. Wallbank, H. Wang, J. Wang, L. Wang, M. H. L. S. Wang, Y. Wang, Y. Wang, K. Warburton, D. Warner, M. Wascko, D. Waters, A. Watson, P. Weatherly, A. Weber, M. Weber, H. Wei, A. Weinstein, D. Wenman, M. Wetstein, A. White, L. H. Whitehead, D. Whittington, M. J. Wilking, C. Wilkinson, Z. Williams, F. Wilson, R. J. Wilson, J. Wolcott, T. Wongjirad, A. Wood, K. Wood, E. Worcester, M. Worcester, C. Wret, W. Wu, W. Wu, Y. Xiao, E. Yandel, G. Yang, K. Yang, S. Yang, T. Yang, A. Yankelevich, N. Yershov, K. Yonehara, T. Young, B. Yu, H. Yu, J. Yu, W. Yuan, R. Zaki, J. Zalesak, L. Zambelli, B. Zamorano, A. Zani, L. Zazueta, G. Zeit, G. P. Zeller, J. Zennamo, K. Zeug, C. Zhang, M. Zhao, E. Zhivun, G. Zhu, P. Zilberman, E. D. Zimmerman, M. Zito, S. Zucchelli, J. Zuklin, V. Zutshi, R. Zwaska and On behalf of the DUNE Collaborationadd Show full author list remove Hide full author list
Instruments 2021, 5(4), 31; https://doi.org/10.3390/instruments5040031 - 29 Sep 2021
Cited by 130 | Viewed by 18070
Abstract
The Deep Underground Neutrino Experiment (DUNE) is an international, world-class experiment aimed at exploring fundamental questions about the universe that are at the forefront of astrophysics and particle physics research. DUNE will study questions pertaining to the preponderance of matter over antimatter in [...] Read more.
The Deep Underground Neutrino Experiment (DUNE) is an international, world-class experiment aimed at exploring fundamental questions about the universe that are at the forefront of astrophysics and particle physics research. DUNE will study questions pertaining to the preponderance of matter over antimatter in the early universe, the dynamics of supernovae, the subtleties of neutrino interaction physics, and a number of beyond the Standard Model topics accessible in a powerful neutrino beam. A critical component of the DUNE physics program involves the study of changes in a powerful beam of neutrinos, i.e., neutrino oscillations, as the neutrinos propagate a long distance. The experiment consists of a near detector, sited close to the source of the beam, and a far detector, sited along the beam at a large distance. This document, the DUNE Near Detector Conceptual Design Report (CDR), describes the design of the DUNE near detector and the science program that drives the design and technology choices. The goals and requirements underlying the design, along with projected performance are given. It serves as a starting point for a more detailed design that will be described in future documents. Full article
Show Figures

Figure 1

8 pages, 1413 KiB  
Article
Camptocormia as a Novel Phenotype in a Heterozygous POLG2 Mutation
by Diana Lehmann Urban, Leila Motlagh Scholle, Kerstin Alt, Albert C. Ludolph and Angela Rosenbohm
Diagnostics 2020, 10(2), 68; https://doi.org/10.3390/diagnostics10020068 - 26 Jan 2020
Cited by 7 | Viewed by 3740
Abstract
Mitochondrial dysfunction is known to play a key role in the pathophysiological pathway of neurodegenerative disorders. Nuclear-encoded proteins are involved in mtDNA replication, including DNA polymerase gamma, which is the only known replicative mtDNA polymerase, encoded by nuclear genes Polymerase gamma 1 ( [...] Read more.
Mitochondrial dysfunction is known to play a key role in the pathophysiological pathway of neurodegenerative disorders. Nuclear-encoded proteins are involved in mtDNA replication, including DNA polymerase gamma, which is the only known replicative mtDNA polymerase, encoded by nuclear genes Polymerase gamma 1 (POLG) and Polymerase gamma 2 (POLG2). POLG mutations are well-known as a frequent cause of mitochondrial myopathies of nuclear origin. However, only rare descriptions of POLG2 mutations leading to mitochondriopathies exist. Here we describe a 68-year-old woman presenting with a 20-year history of camptocormia, mild proximal weakness, and moderate CK increase. Muscle histology showed COX-negative fibres. Genetic analysis by next generation sequencing revealed an already reported heterozygous c.1192-8_1207dup24 mutation in the POLG2 gene. This is the first report on a POLG2 mutation leading to camptocormia as the main clinical phenotype, extending the phenotypic spectrum of POLG2 associated diseases. This underlines the broad phenotypic spectrum found in mitochondrial diseases, especially in mitochondrial disorders of nuclear origin. Full article
(This article belongs to the Section Pathology and Molecular Diagnostics)
Show Figures

Figure 1

14 pages, 1483 KiB  
Article
Cadmium Nephrotoxicity Is Associated with Altered MicroRNA Expression in the Rat Renal Cortex
by Michael J. Fay, Lauren A. C. Alt, Dominika Ryba, Ribhi Salamah, Ryan Peach, Alexander Papaeliou, Sabina Zawadzka, Andrew Weiss, Nil Patel, Asad Rahman, Zyaria Stubbs-Russell, Peter C. Lamar, Joshua R. Edwards and Walter C. Prozialeck
Toxics 2018, 6(1), 16; https://doi.org/10.3390/toxics6010016 - 15 Mar 2018
Cited by 74 | Viewed by 7393
Abstract
Cadmium (Cd) is a nephrotoxic environmental pollutant that causes a generalized dysfunction of the proximal tubule characterized by polyuria and proteinuria. Even though the effects of Cd on the kidney have been well-characterized, the molecular mechanisms underlying these effects have not been fully [...] Read more.
Cadmium (Cd) is a nephrotoxic environmental pollutant that causes a generalized dysfunction of the proximal tubule characterized by polyuria and proteinuria. Even though the effects of Cd on the kidney have been well-characterized, the molecular mechanisms underlying these effects have not been fully elucidated. MicroRNAs (miRNAs) are small non-coding RNAs that regulate cellular and physiologic function by modulating gene expression at the post-transcriptional level. The goal of the present study was to determine if Cd affects renal cortex miRNA expression in a well-established animal model of Cd-induced kidney injury. Male Sprague-Dawley rats were treated with subcutaneous injections of either isotonic saline or CdCl2 (0.6 mg/kg) 5 days a week for 12 weeks. The 12-week Cd-treatment protocol resulted in kidney injury as determined by the development of polyuria and proteinuria, and a significant increase in the urinary biomarkers Kim-1, β2 microglobulin and cystatin C. Total RNA was isolated from the renal cortex of the saline control and Cd treated animals, and differentially expressed miRNAs were identified using µParafloTM microRNA microarray analysis. The microarray results demonstrated that the expression of 44 miRNAs were significantly increased and 54 miRNAs were significantly decreased in the Cd treatment group versus the saline control (t-test, p ≤ 0.05, N = 6 per group). miR-21-5p, miR-34a-5p, miR-146b-5p, miR-149-3p, miR-224-5p, miR-451-5p, miR-1949, miR-3084a-3p, and miR-3084c-3p demonstrated more abundant expression and a significant two-fold or greater increased expression in the Cd-treatment group versus the saline control group. miR-193b-3p, miR-455-3p, and miR-342-3p demonstrated more abundant expression and a significant two-fold or greater decreased expression in the Cd-treatment group versus the saline control group. Real-time PCR validation demonstrated (1) a significant (t-test, p ≤ 0.05, N = 6 per group) increase in expression in the Cd-treated group for miR-21-5p (2.7-fold), miR-34a-5p (10.8-fold), miR-146b-5p (2-fold), miR-224-5p (10.2-fold), miR-3084a-3p (2.4-fold), and miR-3084c-3p (3.3-fold) and (2) a significant (t-test, p ≤ 0.05, N = 6 per group) 52% decrease in miR-455-3p expression in the Cd-treatment group. These findings demonstrate that Cd significantly alters the miRNA expression profile in the renal cortex and raises the possibility that dysregulated miRNA expression may play a role in the pathophysiology of Cd-induced kidney injury. In addition, these findings raise the possibility that Cd-dysregulated miRNAs might be used as urinary biomarkers of Cd exposure or Cd-induced kidney injury. Full article
(This article belongs to the Special Issue Cadmium Sources and Toxicity)
Show Figures

Figure 1

Back to TopTop